- Kane Biotech Inc. (KNE) signs agreements with two U.S. medical universities to study the use of DispersinB
- DispersinB is a naturally occurring enzyme that has been created by Kane.
- The drug candidate will be used to treat patients with prosthetic joint infection (PJI)
- A grant application was submitted to the National Institues of Health for funding pre-clinical work
- Kane Biotech Inc. (KNE) is unchanged trading at $0.12 per share as of 12:11 p.m. EST
Kane Biotech Inc. (KNE) has signed agreements with two U.S. medical universities to study the use of DispersinB.
DispersinB is a naturally occurring enzyme that has been created by Kane and is produced by a wide range of bacteria and fungi.
DispersinB separates inhibiting bacterial bonds and disperses a biofilm. Once the biofilm is dispersed the bacteria can be eradicated and the infection can be alleviated.
DispersinB will be used to treat patients with prosthetic joint infection (PJI).
Josh Wenke, professor at the University of Texas Medical Branch (UTMB) and Dr. James Doub of the University of Maryland School of Medicine’s Institute of Human Virology will be a part of the collaboration. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work which will be done by Wenke.
The Institute of Human Virology has been testing the use of bacteriophage therapeutics, similar to DispersinB, in treating disruptive PJIs with early signals of success.
Dr. Doub stated,
“However, DispersinB has properties that bacteriophages do not have which include superior application as a preventative therapeutic, broader spectrum of activity, and a much easier regulatory [FDA] path.”
A grant application was recently submitted to the NIH for funding pre-clinical work on the candidate drug.
Estimates suggest that PJI will have cost the U.S. healthcare system $1.62 billion in 2020.
The patients have significant morbidity and mortality as a direct result of our current medical and surgical management to treat these infections.
Kane Biotech Inc. (KNE) is unchanged trading at $0.12 per share as of 12:11 p.m. EST.
